ArticleNature communications2023
Molecular features and clinical implications of the heterogeneity in Chinese patients with HER2-low breast cancer.
Article in Nature communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed.
- Soluble HER2 promotes chronic antigen-mediated CD8⁺ T-cell dysfunction and limits immunotherapy response in HER2-low triple-negative breast cancer.Cell death & disease · 2026Article
- ERBB2/HER2 landscape and prognostic impact: large-scale, real-world analysis across solid cancers.ESMO open · 2026Article
- Clinical implications of discordance in HER2 reassessment from HercepTest to 4B5 in metastatic breast cancer.Breast cancer research and treatment · 2026Article
- Clinicopathologic characteristics and genomic profiling of HER2-low advanced gastric or gastroesophageal junction cancer.ESMO open · 2026Article
- Claudin18.2 positive gastric cancer: biology, tumor microenvironment, and therapeutic strategies.Journal of hematology & oncology · 2026Review
- Intratumoral and peritumoral habitat imaging based on multiparametric MRI to predict HER2-negative breast cancer subtypes: a multicenter study.BMC medical imaging · 2026Article
- Proteogenomic Characterization Reveals Subtype-Specific Therapeutic Potential for HER2-Low Breast Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Elevated PTK6 expression is associated with tumor immune microenvironment remodeling and predicts poor prognosis in endometrial carcinoma.Frontiers in medicine · 2026Article
- Prognostic value of RecurIndex in differentiating HER2-low from HER2-negative early-stage breast cancer: a comprehensive clinicopathologic and molecular analysis in Chinese patients.Translational breast cancer research : a journal focusing on translational research in breast cancer · 2026Article
- Antibody-Drug Conjugates in Breast Cancer: Therapeutic-Window Engineering, Tumor Heterogeneity, and Immunotherapy Combinations.Drug design, development and therapy · 2026Review
- Illuminating the clinicopathological and genomic landscape of HER2-null, ultralow, and low breast cancers: insights into diagnostic discordance between biopsy and surgical excision.NPJ breast cancer · 2025Article
- Next-generation sequencing in breast cancer: current clinical applications and future directions.Annals of medicine · 2025Review
- Bibliometric analysis of global research on breast cancer with HER2-low expression.Discover oncology · 2025Article
- Transcriptome Transformer: improving patient survival prediction via multitask learning of transcriptomic and clinical features.Briefings in bioinformatics · 2025Article
- The role of TEAD4 gene in the Hippo signaling pathway in triple-negative breast cancer and targeted therapy strategies.BMC medical genomics · 2025Article
- Antibody-drug conjugates in triple-negative breast cancer (2010-2024): a bibliometric analysis of global trends and clinical translation.Discover oncology · 2025Article
- AI-driven MRI biomarker for triple-class HER2 expression classification in breast cancer: a large-scale multicenter study.Breast cancer research : BCR · 2025Article
- Differences in survival outcomes between HER2-low and HER2-zero breast cancer across heterogeneous HR expression patterns: a real-world study.World journal of surgical oncology · 2025Article
- A Dynamic Contrast-Enhanced MRI-Based Vision Transformer Model for Distinguishing HER2-Zero, -Low, and -Positive Expression in Breast Cancer and Exploring Model Interpretability.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Development and clinical evaluation of [European journal of nuclear medicine and molecular imaging · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The molecular heterogeneity and distinct features of HER2-low breast cancers, particularly in the Chinese population, are not well understood, limiting its precise management in the era of antibody‒drug conjugates. To address this issue, we established a cohort of 434 Chinese patients with HER2-low breast cancer (433 female and one male) and integrated genomic, transcriptomic, proteomic, and metabolomic profiling data. In this cohort, HER2-low tumors are more distinguished from HER2-0 tumors in the hormone receptor-negative subgroup. Within HER2-low tumors, significant interpatient heterogeneity also exists in the hormone receptor-negative subgroup: basal-like tumors resemble HER2-0 disease, and non-basal-like HER2-low tumors mimic HER2-positive disease. These non-basal-like HER2-low tumors are enriched in the HER2-enriched subtype and the luminal androgen receptor subtype and feature PIK3CA mutation, FGFR4/PTK6/ERBB4 overexpression and lipid metabolism activation. Among hormone receptor-positive tumors, HER2-low tumors show less loss/deletion in 17q peaks than HER2-0 tumors. In this work, we reveal the heterogeneity of HER2-low breast cancers and emphasize the need for more precise stratification regarding hormone receptor status and molecular subtype.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.